Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives

by rvvadmin | May 13, 2020 | 2020

TORONTO, May 13, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide a corporate update on...

Revive Therapeutics Provides an Update on its Psilocybin-Based Pharmaceutical Program

by rvvadmin | Apr 29, 2020 | 2020

TORONTO, April 29, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide further insight on...

Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial

by rvvadmin | Apr 23, 2020 | 2020

TORONTO, April 23, 2020 — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has received...

Revive Therapeutics Announces Research Partnership Agreement with the University of Wisconsin-Madison to Evaluate Novel Formulations and Drug Delivery Technology Focused on Psilocybin-Based Pharmaceuticals

by rvvadmin | Apr 21, 2020 | 2020

TORONTO, April 21, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has entered into a...

Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin-Based Pharmaceutical Products

by rvvadmin | Apr 17, 2020 | 2020

TORONTO, April 17, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has engaged...

Revive Therapeutics Announces Closing of Second Tranche of Brokered Private Placement

by rvvadmin | Apr 15, 2020 | 2020

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, April 15, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life...